Z-9040 Zotarolimus, Free Base, >98%

Synonyms : [40-epi-(N1-Tetrazolyl)-rapamycin] [ABT-578] [KY 12420]

Related Terms : [Endeavor] [ZoMaxx]

  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 148
  • 134
  • 112
  • 15,500
  • Add to Cart
  • Out of stock
  • 25 mg
  • 335
  • 304
  • 255
  • 35,000
  • Add to Cart
  • Out of stock
  • 50 mg
  • 685
  • 622
  • 521
  • 71,500
  • Add to Cart
  • Out of stock
  • 250 mg
  • 1,240
  • 1,127
  • 944
  • 129,500
  • Add to Cart
  • Out of stock
  • 500 mg
  • 2,240
  • 2,036
  • 1,706
  • 233,900
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 966.21
  • C52H79N5O12
  • [221877-54-9]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.

  • Zotarolimus (also known as ABT-578) is an analogue of rapamycin (sirolimus) that was designed to have a shorter in vivo half-life than rapamycin. Zotarolimus was found to be comparable in potency for inhibiting in vitro proliferation of both rat and human T cells and mechanistically similar to sirolimus in having high-affinity binding to the immunophilin FKBP12. Chen, Y.W., et al. "Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression." J. Cardiovasc. Pharmacol. 49: 228-235 (2007).
  • In vitro, zotarolimus inhibited FKBP-12 binding (IC50 = 2.8 nM) and potently blocked smooth muscle cell (IC50 = 2.9 nM) and endothelial cell (IC50 = 2.6 nM) proliferation. After 28 days, zotarolimus stents from domestic juvenile swine exhibited less area stenosis (22.4% vs. 35.7%), less neointimal area (1.69 vs. 2.78 mm2), less neointimal thickness (0.25 vs. 0.38 mm), and greater lumen area (6.07 vs. 5.02 mm2) when compared to phosphorylcholine-coated stents. Garcia-Touchard, A., et al. "Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks." Eur. Heart J. 27: 988-993 (2006).
  • Zotarolimus was also designed for use in stents that have phosphorylcholine as a carrier.
  • Zotarolimus is the active drug in the drug-eluting stents sold under the trade name Endeavor® and ZoMaxx®. NOTE: The zotarolimus sold by LC Laboratories is NOT Endeavor® or ZoMaxx®, and is NOT for human use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
  • Please see also our other standard immunosuppressant products: C-6000 Cyclosporin A E-4040 Everolimus F-4633 Fingolimod, Hydrochloride Salt F-4900 FK-506 R-5000 Rapamycin T-8040 Temsirolimus T-1377 Tofacitinib, Free Base